UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
August 15, 2007
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, NY 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o
No
x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
Annual
General Meeting (“AGM”) and Extraordinary General Meeting
(“EGM”)
Notices Posted to Shareholders
Valley
Cottage, New York, August 15, 2007 -
XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical
company engaged in the acquisition, development and commercialization of
therapeutics for the treatment of unmet medical needs, particularly neuropathic
pain and hepatitis C, today announced its has posted to shareholders a
notice
convening its AGM and EGM. The AGM and EGM will take place at the Conference
Room at the Company’s Israeli offices at Building 3, Kiryat Weizmann Science
Park, Rehovot, Israel 76100, at 4:00 p.m. Israel time, and 4:30pm Israel
time,
respectively, on September 25, 2007.
At
the
AGM it is proposed that:
| · |
the
annual reports for the year ended 31 December 2006 be received;
|
| · |
Kesselman
& Kesselman (PricewaterhouseCoopers) be reappointed as the Company's
auditors and the fixing of their remuneration be authorized;
and
|
| · |
Messrs
Michael Weiss, Ben Zion Weiner and William Kennedy be re-appointed
as
Directors of the Company.
|
At
the
EGM it is proposed that:
| · |
the
registered share capital of the Company be increased from 300,000,000
Ordinary Shares to 500,000,000 Ordinary Shares, NIS 0.02 nominal
value
each; and
|
| · |
the
listing of the Company’s Ordinary Shares on the Official List of the
United Kingdom Listing Authority be
cancelled.
|
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the acquisition, development and
commercialization of therapeutics for the treatment of neuropathic pain
and
hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of neuropathic pain. XTL is also
developing several novel pre-clinical hepatitis C small molecule inhibitors.
XTL also has an active in-licensing and acquisition program designed to
identify and acquire additional drug candidates. XTL is publicly traded
on the
NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE:
XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 225
+972-8-930-4444
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | ||
| |
|
|
| Date: August 15, 2007 | By: | /s/ Ron Bentsur |
|
Ron Bentsur |
||
|
Chief
Executive Officer
|
||